Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications drug utilization physician survey intron ® europe
… Multi-Criteria Decision Analysis Most drug development and commercialization choices are complex. … Market Access and Post-Approval Decisions From making drug development decisions, to phase III evidence plans, to …
… patient-reported outcome components in the US, Canada, and Europe, primarily in oncology and neurosciences. Additional …
… MDA’s capabilities in data collection and management, and physician and site recruitment. “This acquisition fits …
… attention Respondents’ self-reported understanding of the survey Failure rate of an internal validity test …
… before gaining regulatory approval by the US Food and Drug Administration to benefit eventual market access. Since … the inclusion of clinical data affect planned or pending publications? Manufacturers should determine the appropriate … and evidence tables). Takeaway 4: Provide patient utilization projections While early dossiers will not …
… models (cost effectiveness, budget impact) Drug utilization studies Economic burden of illness studies …
… areas, from pharmacoepidemiology database projects in Europe to multisite clinical trials to qualitative and … teams and expertise in reproductive health epidemiology, drug utilization studies, vaccine safety, and external comparator …
Navigating EU Joint Clinical Assessments and Joint Scientific Consultations From January 2025 Onward
… plan. The ultimate success of JCAs and market access in Europe will increasingly hinge on including key …
… in the field of pharmacoepidemiology. His experience and publications span many therapeutic areas, including kidney … lecturer on observational study design, large database utilization, and propensity score analysis. Read more about …
… decade has seen an increased focus on patient-centered drug development. Product labeling based on patient-reported … (PRO) endpoints are therefore of special interest to drug manufacturers. The Patient-Centered Outcomes Assessment …